Evidence map›Paper›PMID 38489372›Full record

ArticleScience advances2024

CKLF instigates a "cold" microenvironment to promote MYCN-mediated tumor aggressiveness.

Xiaodan Qin, Andrew Lam, Xu Zhang, Satyaki Sengupta, J Bryan Iorgulescu, Hongru Ni, Sanjukta Das, Madison Rager, Zhenwei Zhou, Tao Zuo and 18 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Molecular principles underlying aggressive cancers.Signal transduction and targeted therapy · 2025
    Review
  7. Molecular regulation and therapeutic targeting ofFrontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 11 institutions in 5 countries.

Xiaodan QinDepartments of Pharmacology, Physiology & Biophysics and Medicine, Section of Hematology and Medical Oncology, Cancer Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-1573-7852
Andrew LamDepartments of Pharmacology, Physiology & Biophysics and Medicine, Section of Hematology and Medical Oncology, Cancer Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0003-0036-7104
Xu ZhangDepartments of Pharmacology, Physiology & Biophysics and Medicine, Section of Hematology and Medical Oncology, Cancer Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-8007-2762
Satyaki SenguptaDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
J Bryan IorgulescuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1405-3667
Hongru NiDepartments of Pharmacology, Physiology & Biophysics and Medicine, Section of Hematology and Medical Oncology, Cancer Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Sanjukta DasDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1339-8487
Madison RagerDepartments of Pharmacology, Physiology & Biophysics and Medicine, Section of Hematology and Medical Oncology, Cancer Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0009-0006-0350-6009
Zhenwei ZhouDepartment of Biostatistics, Boston University School of Public Health, Boston, MA, USA.ORCID 0000-0002-9424-7826
Tao ZuoDepartment of Pathology & Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, MA, USA.ORCID 0000-0002-2125-7548
Grace K MearaDepartments of Pharmacology, Physiology & Biophysics and Medicine, Section of Hematology and Medical Oncology, Cancer Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Alexander E FloruDepartments of Pharmacology, Physiology & Biophysics and Medicine, Section of Hematology and Medical Oncology, Cancer Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-9578-0411
Chinyere KemetDepartments of Pharmacology, Physiology & Biophysics and Medicine, Section of Hematology and Medical Oncology, Cancer Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-5471-9964
Divya VeerapaneniDepartments of Pharmacology, Physiology & Biophysics and Medicine, Section of Hematology and Medical Oncology, Cancer Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-5082-9752
Daniel KashyDepartments of Pharmacology, Physiology & Biophysics and Medicine, Section of Hematology and Medical Oncology, Cancer Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0003-3276-8666
Liang LinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Kenneth LloydInstitute for Protein Innovation, Boston, MA, USA.ORCID 0000-0003-2343-2255
Lauren KwokDepartments of Pharmacology, Physiology & Biophysics and Medicine, Section of Hematology and Medical Oncology, Cancer Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0009-0001-3799-0154
Kaylee S SmithDepartments of Pharmacology, Physiology & Biophysics and Medicine, Section of Hematology and Medical Oncology, Cancer Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Raghavendar T NagarajuFaculty of Biology, Medicine and Health, Division of Cancer Sciences, University of Manchester, Manchester, UK.ORCID 0000-0002-6891-5181
Rob MeijersInstitute for Protein Innovation, Boston, MA, USA.
Craig CeolDepartment of Molecular, Cell and Cancer Biology, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA.ORCID 0000-0002-7188-7580
Ching-Ti LiuDepartment of Biostatistics, Boston University School of Public Health, Boston, MA, USA.ORCID 0000-0002-0703-0742
Sanda AlexandrescuDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-3348-5054
Derin B KeskinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8496-6181
Rani E GeorgeDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Hui FengDepartments of Pharmacology, Physiology & Biophysics and Medicine, Section of Hematology and Medical Oncology, Cancer Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0003-1318-821X
Boston Medical Center · USHarvard University · USBoston University · USInstitute for Protein Innovation · USBoston Children's Hospital · USBrigham and Women's Hospital · USBroad Institute · USManchester Academic Health Science Centre · GBSouth China Agricultural University · CNThe University of Texas MD Anderson Cancer Center · USUniversity of Massachusetts Chan Medical School · US

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI Irene M. Ghobrial · 1985 to 2026
$330.6M
Training Program in Nervous System TumorsK12CA090354 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PLOTKIN, SCOTT R · 2001 to 2025
$16.3M
Systematic identification of minor histocompatibility antigens to address GVHDR01HL157174 · NHLBI · DANA-FARBER CANCER INST · PI HO, VINCENT TRIEN-VINH, KESKIN, DERIN B · 2022 to 2025
$3.0M
The Role of DLST in LeukemogenesisR01CA215059 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FENG, HUI · 2018 to 2022
$2.0M
Cell lineage as an indicator of immune response in neuroblastomaR01CA271605 · NCI · DANA-FARBER CANCER INST · PI Rani E. George · 2022 to 2026
$2.0M
Cellular and molecular regulators of melanocyte regenerationR01AR081355 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Craig Joseph Ceol · 2023 to 2026
$1.3M
"Oncorequisite" Genes in MYC-mediated TransformationR00CA134743 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FENG, HUI · 2012 to 2014
$712k
The Role of DLST in LeukemogenesisR56CA215059 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FENG, HUI · 2017 to 2017
$376k
"Oncorequisite" Genes in MYC-mediated TransformationK99CA134743 · NCI · DANA-FARBER CANCER INST · PI FENG, HUI · 2009 to 2010
$282k
NCI NIH HHS K12 CA090354NCI NIH HHS K99 CA134743NCI NIH HHS P30 CA006516NCI NIH HHS R00 CA134743NCI NIH HHS R01 CA215059NCI NIH HHS R01 CA271605NCI NIH HHS R56 CA215059NHLBI NIH HHS R01 HL157174NIAMS NIH HHS R01 AR081355
6 · The paper itself

Abstract

Solid tumors, especially those with aberrant MYCN activation, often harbor an immunosuppressive microenvironment to fuel malignant growth and trigger treatment resistance. Despite this knowledge, there are no effective strategies to tackle this problem. We found that chemokine-like factor (

Indexed as

ChemokinesMARVEL Domain-Containing ProteinsNeuroblastomaN-Myc Proto-Oncogene ProteinCell Line, TumorGene Expression Regulation, NeoplasticHumansTumor MicroenvironmentChemokinesCKLF protein, humanMARVEL Domain-Containing ProteinsMYCN protein, humanN-Myc Proto-Oncogene Protein

Identifiers

PMID38489372
PMCPMC10942121
OpenAlexW4392861816

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.